Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

McGuirk JP, Ghobadi A, Bachier CR, Shaughnessy PJ, Awan F, Maakaron JE, Bishop MR, Ho PJ, Tam CS, Dickinson M, Darrah JM, Waller EK, Murthy HS, Ross A, Williams LM, Pan C, Stevens WN, Serwer L, Nguyen T, Terrett J, Kalaitzidis D, Ma A, Xu H, Benton M, Weaver A, Cohen SB, Maziarz RT, Cheah C

Open source

DOI: 10.1182/bloodadvances.2026020123
Published: 2026 Sep 8
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026020123,
  title = {Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.},
  author = {McGuirk JP and Ghobadi A and Bachier CR and Shaughnessy PJ and Awan F and Maakaron JE and Bishop MR and Ho PJ and Tam CS and Dickinson M and Darrah JM and Waller EK and Murthy HS and Ross A and Williams LM and Pan C and Stevens WN and Serwer L and Nguyen T and Terrett J and Kalaitzidis D and Ma A and Xu H and Benton M and Weaver A and Cohen SB and Maziarz RT and Cheah C},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2026020123},
  url = {https://doi.org/10.1182/bloodadvances.2026020123}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
AU  - McGuirk JP
AU  - Ghobadi A
AU  - Bachier CR
AU  - Shaughnessy PJ
AU  - Awan F
AU  - Maakaron JE
AU  - Bishop MR
AU  - Ho PJ
AU  - Tam CS
AU  - Dickinson M
AU  - Darrah JM
AU  - Waller EK
AU  - Murthy HS
AU  - Ross A
AU  - Williams LM
AU  - Pan C
AU  - Stevens WN
AU  - Serwer L
AU  - Nguyen T
AU  - Terrett J
AU  - Kalaitzidis D
AU  - Ma A
AU  - Xu H
AU  - Benton M
AU  - Weaver A
AU  - Cohen SB
AU  - Maziarz RT
AU  - Cheah C
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2026020123
UR  - https://doi.org/10.1182/bloodadvances.2026020123
ER  -

APA

JP, M., A, G., CR, B., PJ, S., F, A., JE, M., MR, B., PJ, H., CS, T., M, D., JM, D., EK, W., HS, M., A, R., LM, W., C, P., WN, S., L, S., T, N., J, T., D, K., A, M., H, X., M, B., A, W., SB, C., RT, M., & C, C. (2026). Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.. Blood advances. https://doi.org/10.1182/bloodadvances.2026020123

Source records

pubmed · retrieved 2026-09-27T00:42:36.239Z